psoriasis disease severity in patients with mild to moderate disease (ie, median BSA involvement of 3.0%).5 A responsiveness to change analysis indicated that PGAxBSA and PASI had similar abilities to capture changes in disease severity. However, response to therapy could not be determined in this study due to the different treatments used in the registry. Similar findings were reported in a retrospective multicenter study using data from the Dermatology Clinical Effectiveness Research Network (DCERN), a consortium of private and academic centers of dermatologists in the United States, that included patients with 
